SAN

82.48

-0.46%↓

UCB

265.3

-0.97%↓

SHL.DE

35.94

-1.21%↓

ARGX

645.6

+0.47%↑

VIE

33.34

+0.33%↑

SAN

82.48

-0.46%↓

UCB

265.3

-0.97%↓

SHL.DE

35.94

-1.21%↓

ARGX

645.6

+0.47%↑

VIE

33.34

+0.33%↑

SAN

82.48

-0.46%↓

UCB

265.3

-0.97%↓

SHL.DE

35.94

-1.21%↓

ARGX

645.6

+0.47%↑

VIE

33.34

+0.33%↑

SAN

82.48

-0.46%↓

UCB

265.3

-0.97%↓

SHL.DE

35.94

-1.21%↓

ARGX

645.6

+0.47%↑

VIE

33.34

+0.33%↑

SAN

82.48

-0.46%↓

UCB

265.3

-0.97%↓

SHL.DE

35.94

-1.21%↓

ARGX

645.6

+0.47%↑

VIE

33.34

+0.33%↑

Kodu・Aktsiate loetelu・Nanobiotix

N
Nanobiotix

Suletud

27.5 -4.01

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

27.4

Max

27.85

Põhinäitajad
By Trading Economics
Sissetulek	-5.4M
Müük	27M
Kasumimarginaal	-20.208
Töötajad	103
EBITDA	1.1M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+16.79% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	20. mai 2026

Turustatistika
By TradingEconomics
Turukapital	1.3B
Eelmine avamishind	31.51
Eelmine sulgemishind	27.5

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

2.975 / 3.015 Toetus ja vastupanu

Nanobiotix Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. apr 2026, 04:27 UTC

Uudisväärsed sündmused

Singapore PM Warns That Fallout From Mideast War Could Outlast Conflict

3. apr 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3. apr 2026, 18:30 UTC

Uudisväärsed sündmused

An F15-E Just Went Down in Iran. What to Know About the $30 Million Jet. -- Barrons.com

3. apr 2026, 18:14 UTC

Market Talk

Eli Lilly Seen as Possible GLP-1 Leader With New Pill Approval -- Market Talk

3. apr 2026, 17:50 UTC

Market Talk

Microsoft's AI Development Will Weigh on Near-Term Azure Growth -- Market Talk

3. apr 2026, 17:44 UTC

Omandamised, ülevõtmised, äriostud

SBA Stock Just Had a Big Day. Why It's Suddenly Hot. -- Barrons.com

3. apr 2026, 16:50 UTC

Uudisväärsed sündmused

An F15-E Just Went Down in Iran. What to Know About the $90 Million Jet. -- Barrons.com

3. apr 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3. apr 2026, 16:12 UTC

Tulu

Oil Stocks Look Tapped Out. Why It's Time to Move Into Other Sectors. -- Barrons.com

3. apr 2026, 15:56 UTC

Market Talk

Uudisväärsed sündmused

Crypto Markets May Be Active Over Holiday Weekend -- Market Talk

3. apr 2026, 15:56 UTC

Market Talk

Uudisväärsed sündmused

Global Equities Roundup: Market Talk

3. apr 2026, 15:56 UTC

Market Talk

Uudisväärsed sündmused

Global Forex and Fixed Income Roundup: Market Talk

3. apr 2026, 15:20 UTC

Uudisväärsed sündmused

Berkshire, Travelers Join U.S. Plan to Insure Shippers in the Hormuz Strait -- Barrons.com

3. apr 2026, 15:08 UTC

Omandamised, ülevõtmised, äriostud

OpenAI Makes Surprise Media Acquisition Ahead of IPO. Why It Will Fail. -- Barrons.com

3. apr 2026, 14:11 UTC

Market Talk

Uudisväärsed sündmused

Oil Shock From War in Iran May Show Up In 2Q Job Growth Data -- Market Talk

3. apr 2026, 12:56 UTC

Market Talk

Treasury Yields, Dollar Higher Following Robust March Hiring -- Market Talk

3. apr 2026, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3. apr 2026, 08:01 UTC

Market Talk

Global Equities Roundup: Market Talk

3. apr 2026, 08:01 UTC

Market Talk

Meituan's Profitability Likely to Improve This Year -- Market Talk

3. apr 2026, 07:45 UTC

Market Talk

LG Electronics Could Post Above-Consensus 1Q Earnings -- Market Talk

3. apr 2026, 06:17 UTC

Market Talk

Naver Likely to Post Below-Consensus 1Q Earnings -- Market Talk

3. apr 2026, 06:17 UTC

Market Talk

Global Equities Roundup: Market Talk

3. apr 2026, 04:33 UTC

Market Talk

China Merchants Port Earnings Likely to Recover This Year -- Market Talk

3. apr 2026, 04:33 UTC

Market Talk

Global Equities Roundup: Market Talk

3. apr 2026, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

3. apr 2026, 04:01 UTC

Market Talk

Posco Holdings 1Q Earnings Could Fall Short of Expectations -- Market Talk

3. apr 2026, 02:01 UTC

Market Talk

India Consumer-Staple Companies Likely to Post Broadly Steady 4Q Results -- Market Talk

3. apr 2026, 01:59 UTC

Market Talk

Sea's Shopee E-Commerce Platform Likely in Reinvestment Phase -- Market Talk

3. apr 2026, 01:44 UTC

Market Talk

Samsung Likely to Report Record Quarterly Earnings in 2026 -- Market Talk

3. apr 2026, 01:22 UTC

Market Talk

Dollar Could Hit 160 Yen in Thin Holiday Trading -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Nanobiotix Prognoos

Hinnasiht

By TipRanks

16.79% tõus

12 kuu keskmine prognoos

Keskmine 32 EUR 16.79%

Kõrge 32 EUR

Madal 32 EUR

Põhineb 1 Wall Streeti analüütiku instrumendi Nanobiotix 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Nanobiotix aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

2.975 / 3.015Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.